Market Trends of Non-opioid Pain Patch Industry
Lidocaine Patches Segment is Expected to Show Significant Market Growth Over the Forecast Period
Lidocaine patches are the most commonly available for treating chronic and acute pain. Factors such as the rise in the prevalence of pain and product launches by key market players are expected to boost the segment’s growth.
Furthermore, various clinical studies are being conducted to demonstrate the efficacy of lidocaine patches in postoperative pain management, which is expected to bolster market growth over the forecast period. For instance, as per the article published in September 2022 by PubMed, researchers demonstrated that the 5% lidocaine patch is efficacious in acute postoperative pain after unilateral inguinal hernia repair. Thus, such advantages offered by the lidocaine patches are expected to increase market demand and fuel market growth over the forecast period.
Moreover, increasing product launches by key market players are anticipated to boost the market. For instance, in June 2022, Hisamitsu America, a subsidiary of Hisamitsu Pharmaceutical Co. Inc., and the manufacturers of the Salonpas line of pain relief products established the availability of the Salonpas Pain Relieving FLEX Patch Lidocaine 4% featuring thin, flexible, and highly adhesive patch technology.
Similarly, in August 2022, Scilex Holding Company, a commercial biopharmaceutical company, focused on developing and commercializing non-opioid therapies for acute and chronic pain patients. It received the fast-track designation for its investigational drug and device product candidate, SP-103. Scilex is developing SP-103 as a non-opioid triple-strength, non-aqueous lidocaine topical system for treating acute LBP. If approved, SP-103 could become the first FDA-approved lidocaine topical product for treating acute LBP. In addition, the increasing burden of diseases, along with the safety profile and efficacy associated with lidocaine patches, are expected to drive the growth of the non-opioid pain patch market during the forecast period.
Therefore, due to the high efficacy of lidocaine patches and the key players' strategic activities, the segment is anticipated to witness significant growth over the forecast period.
North America is Expected to Witness Healthy Growth in the Non-opioid Pain Patch Market Over the Forecast Period
North America is expected to witness significant growth due to the rising prevalence of pain-related diseases and product launches by key market players in the region.
Chronic pain is one of the primary factors responsible for the market's growth. According to the study published in the JAMA Network in February 2022, it was estimated that one in every five adults in the United States suffered from chronic pain. One in 14 adults experienced severe chronic pain. In addition, countries in North America are increasingly facing scrutiny on the opioid crisis issue from government authorities, which, in turn, is expected to increase the demand for non-opioid alternatives. Thus, the rising disease burden further pushes the need for effective and quick treatment options, which is expected to propel the market's growth over the forecast period.
Similarly, chronic pain, such as nerve pain, chronic pelvic pain, pain related to endometriosis, carpal tunnel syndrome, pain related to gout, and cancer pain, were studied using a variety of complementary therapies. One of the most common cases in North America is cancer-related pain. Thus, the rise in cancer cases is expected to augment market growth over the forecast period. For instance, according to the American Cancer Society 2024 Cancer Statistics, the number of new cancer cases is estimated to be 2.00 in the United States in 2024, up from 1.93 million in 2023. The high burden of cancer is expected to augment the demand for non-opioid pain patches for reducing cancer pain, thereby boosting market growth over the forecast period.
In addition, product launches by key market players are anticipated to boost market growth during the forecast period. For instance, in January 2023, Yaral Pharma Inc., the US generics subsidiary of IBSA, a long-standing, multinational pharmaceutical company, launched diclofenac epolamine topical system 1.3%, the authorized generic of IBSA Pharma's Flector (diclofenac epolamine) topical system. Diclofenac epolamine topical system 1.3% is a prescription nonsteroidal anti-inflammatory (NSAID) medicated patch indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions.
In February 2022, NEXGEL Inc., a provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, reported the launch of its MEDAGEL Bug Bite Relief Patch. These cooling patches, made in the United States using NEXGEL's soothing hydrogel technology, provide instant relief to irritated skin caused by insect bites.
Thus, due to the high prevalence of pain-related diseases and strategic activities by the key players, the region is anticipated to witness significant growth over the forecast period.
